6533b7cffe1ef96bd1257ce4
RESEARCH PRODUCT
Antiretroviral therapy abrogates association between arginase activity and HIV disease severity
Tom ClokeMarkus MunderAsrat HailuIngrid MüllerTamrat AbebeGraham P. TaylorPascale Kropfsubject
MaleAnti-HIV AgentsT cellT cellsCD4 cell countL-arginineHIV InfectionsArgininePeripheral blood mononuclear cellSeverity of Illness Index03 medical and health sciences0302 clinical medicineImmune systemImmunopathologymedicineHumansImmune response030304 developmental biology0303 health sciencesbiologyArginasebusiness.industryPublic Health Environmental and Occupational HealthHIVGeneral MedicineViral Loadbiology.organism_classification3. Good healthCD4 Lymphocyte CountArginaseInfectious Diseasesmedicine.anatomical_structureSociety Meeting PaperLentivirusImmunologyHIV-1Leukocytes MononuclearParasitologyFemaleViral diseasebusinessViral load030217 neurology & neurosurgerydescription
AbstractArginase-induced L-arginine deprivation is emerging as a key mechanism for the downregulation of immune responses. We hypothesised that arginase activity increases with disease severity in HIV-seropositive patients. Our results show that peripheral blood mononuclear cells (PBMCs) from 23 HIV-seropositive patients with low CD4+ T cell counts (≤350 cells/μl) expressed significantly more arginase compared with 21 patients with high CD4+ T cell counts. Furthermore, we found a significant association between the two principal prognostic markers used to monitor HIV disease (CD4+ T cell count and plasma viral load) and PBMC arginase activity in antiretroviral therapy naïve patients but not in patients undergoing therapy.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2010-11-01 | Transactions of the Royal Society of Tropical Medicine and Hygiene |